title: Restarting Dabigatran Etexilate 24 h After Reversal With Idarucizumab and Redosing Idarucizumab in Healthy Volunteers.
authors.forename: Stephan
authors.initials: S
authors.lastname: Glund
authors.forename: Joachim
authors.initials: J
authors.lastname: Stangier
authors.forename: Joanne
authors.initials: J
authors.lastname: van Ryn
authors.forename: Michael
authors.initials: M
authors.lastname: Schmohl
authors.forename: Viktoria
authors.initials: V
authors.lastname: Moschetti
authors.forename: Wouter
authors.initials: W
authors.lastname: Haazen
authors.forename: Marina
authors.initials: M
authors.lastname: De Smet
authors.forename: Dietmar
authors.initials: D
authors.lastname: Gansser
authors.forename: Stephen
authors.initials: S
authors.lastname: Norris
authors.forename: Benjamin
authors.initials: B
authors.lastname: Lang
authors.forename: Paul
authors.initials: P
authors.lastname: Reilly
authors.forename: Jörg
authors.initials: J
authors.lastname: Kreuzer
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000494:pharmacology*; D000991:Antithrombins / Q000494:pharmacology; D018592:Cross-Over Studies; D000069604:Dabigatran / Q000494:pharmacology*; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D016903:Drug Monitoring / Q000379:methods; D064420:Drug-Related Side Effects and Adverse Reactions / Q000628:therapy*; D005260:Female; D064368:Healthy Volunteers; D006801:Humans; D008297:Male; D008875:Middle Aged; D019233:Retreatment / Q000379:methods*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D000991:Antithrombins; C000594745:idarucizumab; D000069604:Dabigatran